We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at ...

A wave of new drugs have revolutionised the weight loss industry. Now, getting your hands on one popular medication could get ...

The U.S. stock market continued to rebound from a period of volatility for the second straight week, with the S&P 500 closing ...

The S&P 500 clinched its longest winning streak since 2004. The week ahead will see the Federal Reserve put that to the test.

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...